1 Serotonin 5-HT 7 receptors are present in astrocytes. Understanding their role in this type of cell would greatly benefit from the identification of astroglial cell lines expressing this receptor type. 2 The aim of the present study was to assess the expression of native 5-HT 7 receptors and 5-HT 7 receptor mRNA in a number of human glioblastoma cell lines, by means of cAMP measurements, Western blot analysis and reverse transcriptase-polymerase chain reaction (RT-PCR) analysis. 
Introduction
Receptors for serotonin (5-hydroxytryptamine (5-HT)) are classified into seven major classes (5-HT 1-7 ), based on structural, functional and pharmacological criteria (Hoyer et al., 1994) . The 5-HT 7 receptor, cloned from mouse (Plassat et al., 1993) , rat (Lovenberg et al., 1993; Meyerhof et al., 1993; Ruat et al., 1993; Shen et al., 1993) , guinea-pig (Tsou et al., 1994) and human (Bard et al., 1993) , is positively coupled to adenylyl cyclase and cAMP accumulation through the stimulatory G protein G s and displays a unique pharmacological profile which is consistent across species. Sequence alignment shows a high degree of interspecies homology (95%) but a low overall homology (o40%) with other 5-HT receptors. A number of splice variants of both the human (5-HT 7(a/b/d) ) and rat (5-HT 7(a/b/c) ) receptors have been identified. They display similar pharmacological and functional characteristics when expressed in cell lines, and a similar tissue distribution (Heidmann et al., 1997; Jasper et al., 1997; Krobert et al., 2001) . The most abundant isoform (5-HT 7(a) ) consists of a 445-amino-acid polypeptide with a relatively short third intracellular loop and a long carboxy-terminus.
The 5-HT 7 receptor mRNA has been found in the brain, where it is located in the thalamus, hypothalamus and various limbic and cortical regions in rat (Lovenberg et al., 1993; Ruat et al., 1993; Shen et al., 1993) , guinea-pig and man (Bard et al., 1993; Hagan et al., 2000) , as well as in smooth muscles from cardiovascular and gastrointestinal tissues (Bard et al., 1993; Schoeffter et al., 1996; Hagan et al., 2000) . Receptor distribution and pharmacological studies have suggested that 5-HT 7 receptors may play a role in the control of circadian rhythms (Lovenberg et al., 1993; Ying & Rusak, 1997) and smooth muscle tone . As far as the nervous system is concerned, selective 5-HT 7 receptor ligands may have potential therapeutic applications in sleep disorders, depression, migraine and pain (for a review, see Thomas & Hagan, 2004) .
Electrophysiological studies have shown that 5-HT 7 receptors modulate neuronal function in slices of rat hippocampus (Bacon & Beck, 2000; Gill et al., 2002) and thalamus (Chapin & Andrade, 2001; Goaillard & Vincent, 2002) . Besides this neuronal localization, there is also evidence that 5-HT 7 receptors are present in glial cells. Primary cultures of rat (Shimizu et al., 1996; Hirst et al., 1997) and human (Cohen et al., 1999) brain astrocytes express these receptors. Glial 5-HT 7 receptors have also been detected in situ in the mouse suprachiasmatic nucleus by electron microscopic immunocytochemistry (Belenky & Pickard, 2001) . Although astrocytes have long been regarded as neuron-supporting, ancillary cells in the brain, their active role in reciprocal neuron-glia interactions is being increasingly recognized. They now appear to be regulators of synaptic activity, synaptogenesis and neurogenesis. However, the molecular pathways involved in this regulatory activity are poorly understood (for a review, see Ransom et al., 2003) .
In this context, the knowledge of the role of astroglial 5-HT 7 receptors would greatly benefit from the identification of cell lines expressing this receptor type, as has been the case with rat C 6 glioma cells for the 5-HT 2A receptor (Elliott et al., 1995) . It was the aim of the present study to assess the expression of native 5-HT 7 receptors and 5-HT 7 receptor mRNA in a number of human glioblastoma cell lines, by means of cAMP measurements, Western blot analysis and reverse transcriptase-polymerase chain reaction (RT-PCR) analysis.
Methods

Cell lines and culture
The human glioblastoma cell lines, U-373 MG, U-138 MG, U-87 MG, DBTRG-05MG, T98G, H4, CCF-STTG1 and Hs 683 were purchased from the American Type Culture Collection (Rockville, MD, U.S.A.). Dulbecco's modified Eagle medium (DMEM), minimum essential medium (MEM), RPMI 1640 medium and non-essential amino acids were purchased from Gibco BRL Life Technologies (Rockville, MD, U.S.A.). The glioblastoma cell lines U-373 MG, U-138 MG, U-87 MG, T98G and DBTRG-05MG were maintained in MEM, supplemented with non-essential amino acids, the H4 and Hs 683 cell lines in DMEM and the CCF-STTG1 cell line in RPMI 1640 medium. All media were supplemented with 10% foetal calf serum, penicillin G (100 U ml
À1
) and streptomycin (100 mg ml
). Cells were grown at 371C in a humidified atmosphere containing 5% CO 2 . For cAMP measurements, the cells were subcultured in 24-well plates. For RT-PCR and Western blot experiments, cells were subcultured in six-well culture plates.
cAMP measurements and analysis of data cAMP accumulation was measured in intact cells seeded in 24-well plates, using the standard [ 3 H]adenine prelabelling technique, as described previously (Schoeffter et al., 1997; . Cells were deprived of serum 24 h before the assay. They were incubated with agonists/antagonists for 15 min in the presence of 1 mM isobutylmethylxanthine. The [
. ratio (cAMP conversion rate) was calculated for each sample. Concentration-response curves were fitted to the nonlinear logistic function of the Origin 6.1 software package (OriginLab Corporation, Northampton, MA, U.S.A.). E max and EC 50 values were derived from these analyses. Results are given as mean values7s.e.m. of the indicated n number of experiments. The pA 2 values of the antagonist compound (R)-3-(2-(2-(4-methylpiperin-1-yl)-ethyl)pyrrolidine-1-sulphonyl)phenol (SB-269970) were estimated from Schild analyses (Arunlakshana & Schild, 1959) . Incomplete curves in the presence of the highest concentration of the antagonist were constrained to the E max of the control curve to obtain EC 50 estimates.
Western blot analysis
Cells were first washed twice with cold phosphate-buffered saline and then scraped in 100 ml of a buffer containing 20 mM Tris at pH 8, 137 mM NaCl, 1% Nonidet P40, 10% glycerol, 0.5 mM orthovanadate, 1 mM phenylmethane sulphonyl fluoride and a protease inhibitor cocktail (Roche Diagnostics, Mannheim, Germany), sonicated and centrifuged at 13,000 r.p.m. for 5 min at 41C. The proteins (25 mg per lane) were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) on a 4-20% Tris-glycine polyacrylamide gel (Cambrex, Rockland, ME, U.S.A.) and transferred onto a PVDF membrane. The membranes were blocked with blocking buffer, consisting of 5% milk, 1% BSA in TBST buffer (0.2 mM Tris-HCl, pH 7.5, 150 mM NaCl and 0.05% Tween 20) and then incubated for 2 h with a rabbit polyclonal antibody to the serotonin 5-HT 7 receptor (Imgenex, San Diego, CA, U.S.A.) diluted in TBST to a final concentration of 0.5 mg ml
À1
. This antibody was raised against a sequence identical for all human receptor splice variants. Membranes were then washed and incubated for 1 h with an anti-rabbit peroxidase-conjugated antibody (Sigma-Aldrich, Buchs, Switzerland) diluted 1 : 100,000 in blocking buffer, followed by application of an enhanced chemiluminescent system (Socochim SA Supersignal s West Femto, Pierce, Perbio Science, Lausanne, Switzerland).
Primers for polymerase chain reaction (PCR)
To identify the three splice variants of the human 5-HT 7 receptor (which differ from each other only by their carboxyterminus tails), primers were designed in such a way that the length of the amplification products was specific to each splice variant:
The sequences of the primers were as follows: 
RNA extraction and RT-PCR analysis
Total RNA was isolated from glioblastoma cell lines by using the SNAPt Total RNA Isolation Kit (Invitrogen, Carlsbad, CA, U.S.A.). The quantity of total RNA was determined by Ribogreen s staining (Ribogreent RNA Quantitation Kit; Molecular Probes, Inc., Eugene, OR, U.S.A.). The quality of the RNA was checked by electrophoretic separation of the RNA on a 1.2% SeaKem LE agarose gel (Karlan, Santa Rosa, CA, U.S.A.). For each RNA sample, 400 ng of total RNA was first digested with DNAse I (Qiagen, Hilden, Germany) in order to remove traces of genomic DNA contamination. The DNAse I enzyme was inactivated by addition of EDTA and heating up to 651C for 2 min. DNAse I-treated total RNA was reverse transcribed into cDNA for 60 min at 421C with 300 ng of random hexamer primers and 50 U of StrataScriptt reverse transcriptase (Stratagene, La Jolla, CA, U.S.A.). The reaction was stopped by heating up to 951C for 5 min. In all, 20 ng of RNA/cDNA was used as template for the PCR. PCR amplification was performed in a final volume of 20 ml containing 130 mM of dNTPs, 0.5 mM of each primers, 1 U of Taq DNA polymerase (Amersham Biosciences Europe, Otelfingen, Switzerland) and its corresponding buffer. The PCR amplification took place in a Biometra thermocycler with the following conditions: initial denaturation at 951C for 5 min, then 40 cycles with the following profile: 951C for 40 s, 601C for 40 s and 721C for 40 s, final extension at 721C for 7 min. After amplification, the PCR products were separated electrophoretically on a 3% NuSieve 3 : 1 agarose gel and visualized by ethidium bromide staining. Each RT-PCR product was excised from agarose gels, extracted and purified using the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany). The eluted DNA fragments were sequenced by A Wanner (Novartis Sequencing Facility).
Drugs 5-Hydroxytryptamine creatinine sulphate (5-HT), 5-carboxamidotryptamine maleate (5-CT) and 8-hydroxy-2-(di-n-propylamino)tetralin hydrobromide (8-OH-DPAT) were obtained from Sigma-Aldrich (Buchs, Switzerland). 5-Methoxytryptamine (5-MeOT) and (SB-269970) hydrochloride were synthesized at Novartis Pharma AG, Basel. Millimolar stock solutions of test compounds were made on the day of the experiment in dimethylsulphoxide or distilled water. Further dilutions were made in distilled water. (Table 1) .
Results
Identification
Concentration-response relationships for cAMP stimulation were obtained using the four agonists 5-HT, 5-CT, 5-MeOT and 8-OH-DPAT. Results with U-373 MG, DBTRG-05MG, T98G and H4 cells are illustrated in Figure 1 . The rank order of potency was 5-CT45-HT ¼ 5-MeOTb8-OH-DPAT in these cell lines. Similar potencies were found for 5-CT and 5-HT in U-138 MG, U-87 MG, CCF-STTG1 and Hs 683 ( Table 1) .
The potent and selective 5-HT 7 receptor antagonist SB-269970 (10 nM-1 mM) induced incremental shifts in the concentration-response curve of 5-CT to the right in a parallel manner in all cell lines. Data with U-373 MG, DBTRG-05MG, T98G and H4 cells are illustrated in Figure 2 . Schild analyses yielded slope factors close to unity (0.89-1.13) and pA 2 values in the range 8.69-9.05 (Table 1) .
Western blot analysis
Western blot analysis was performed to investigate the occurrence of the 5-HT 7 receptor protein in human glioblastoma cells. The antiserum revealed two bands with apparent molecular masses of approximately 45 and 50 kDa in extracts of Chinese hamster ovary (CHO) cells stably transfected with the human 5-HT 7(a) receptor cDNA, but not in untransfected CHO cells (Figure 3a) . These two bands were also present in extracts of all the human glioblastoma cell lines tested, with the exception of Hs 683 cells for which only the 50 kDa band was Data are mean values7s.e.m. from three or four individual experiments. Maximal effects are expressed as fold increases above basal cAMP accumulation. Since no maximum was reached for 8-OH-DPAT (see Figure 1) , pEC 50 values for this agonist are rough estimates. ND, not determined.
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C. Mahé et al 5-HT 7 receptors in human glioblastoma cell lines apparent (Figure 3b ). This pattern of data was observed in at least two independent experiments for each cell line.
Reverse transcriptase-polymerase chain reaction (RT-PCR)
The presence of the different splice variants of the 5-HT 7 receptor was investigated by RT-PCR analysis with specific primers that give specific amplification products for each of them (5-HT 7(a) , 5-HT 7(b) and 5-HT 7(d) ). As a control, the cDNA of the constitutively expressed b-actin gene was also amplified. Three cDNA bands of the expected sizes (506 bp for 5-HT 7(a) , 546 bp for 5-HT 7(b) and 639 bp for 5-HT 7(d) ) were amplified in the reverse transcribed products from all human glioblastoma cell lines tested (Figure 4) . The band corresponding to the 5-HT 7(d) splice variant consistently appeared to be less intense than the others. The different bands obtained for each cell line were excised, re-amplified with the same primers and sequenced. Sequencing confirmed that the PCR products corresponded to the amplification of the three cDNA splice variants in all cell lines. This pattern of data was observed in at least two independent experiments for each cell line.
Discussion
The objective of the present study was to assess the validity of human glioblastoma cell lines as model systems for the study of 5-HT 7 receptors in astroglial cells. Functional 5-HT 7 receptors and 5-HT 7 receptor mRNA are known to be present and expressed in human and rat brain astrocytes (Shimizu et al., 1996; Hirst et al., 1997; Cohen et al., 1999) . However, such primary cells cannot be propagated in culture and are therefore of limited help for extensive and detailed investigations. The present results show that several human glioblastoma cell lines (U-373 MG, U-138 MG, U-87 MG, In functional studies with human glioblastoma cells, the rank order of agonist potency for stimulation of cAMP accumulation was 5-CT45-HT ¼ 5-MeOTb8-OH-DPAT. This is the 'fingerprint' of 5-HT 7 receptors. Of the three 5-HT receptor classes positively coupled to adenylyl cyclase (5-HT 4 , 5-HT 6 and 5-HT 7 ), 5-HT 7 is the only one showing higher affinity for 5-CT than for 5-HT (see Hoyer et al., 1994) . The relatively low pEC 50 values of agonists in glioblastoma cells, as compared to their affinities for the cloned 5-HT 7 receptor (Bard et al., 1993) , are probably to be ascribed to a limited number of receptors in the former situation. In line with this view, it is pertinent to say that no specific radioligand binding could be detected in human glioblastoma cells, using [ have been observed at native 5-HT 7 receptors in rat primary astrocytes (Hirst et al., 1997) .
Definitive evidence that the effect of 5-CT is mediated by 5-HT 7 receptors in human glioblastoma cells was shown in antagonist studies with SB-269970. This compound has been introduced as a potent and selective 5-HT 7 receptor antagonist, with a pK i value of 8.9 and a functional pA 2 value of 8.5 (Hagan et al., 2000; Lovell et al., 2000) . Values of pA 2 found in human glioblastoma cells (8.69-9.05) were quite in line with these reported data.
To confirm the expression of 5-HT 7 receptors in the human glioblastoma cells, the presence of this protein was then investigated by Western blotting, using a specific antibody raised against a sequence identical for all human receptor splice variants. Two bands, with apparent molecular masses of approximately 45 and 50 kDa, were detected for all glioblastoma cells except for Hs 683 cells, in which only the upper band was observed. These two bands were also present in CHO cells stably transfected with the human 5-HT 7 receptor cDNA. The 45-50 kDa range corresponds to the anticipated molecular mass of the 5-HT 7 receptor, which in addition 
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C. Mahé et al 5-HT 7 receptors in human glioblastoma cell lines possesses two putative sites for N-linked glycosylation in its amino-terminal region and several putative sites for phosphorylation (Boess & Martin, 1994) . The results suggest that two protein forms of the 5-HT 7 receptor are expressed in human glioblastoma cells (and control CHO cells), perhaps with different degrees of glycosylation and/or phosphorylation. For some reason, Hs 683 cells do not express one of these forms. Pharmacological and immunological detection of 5-HT 7 receptors in human glioblastoma cells was corroborated by results of molecular biology studies, showing the presence of the three splice variants of the human 5-HT 7 receptor. RT-PCR amplifications were conducted using specific primers designed in such a way that the length of the amplification products was specific for each splice variant of the human 5-HT 7 receptor. Three bands of the expected sizes were generated, suggesting the presence of the three splice variants in all glioblastoma cell lines. Sequencing of the different bands confirmed that the amplified fragments correspond to the cDNA sequences of the human 5-HT 7 receptor splice variants. The 5-HT 7(a) and 5-HT 7(b) splice variants seem to be predominantly expressed in all glioblastoma cells compared to the 5-HT 7(d) variant, in agreement with findings in some other tissues, including the brain (Heidmann et al., 1997; Krobert et al., 2001) .
Taken together, the present results indicate that human glioblastoma cells may be used as model systems of native astroglial 5-HT 7 receptors. The physiological role of these astroglial receptors, as pointed out in earlier studies, remains speculative (Hirst et al., 1997) . The various 'classical' functions of glial cells include nutritive support for neurons and uptake of excess neurotransmitters and K þ . However, glial cells now appear to be involved in a broader spectrum of neuronassociated processes, for example, synaptogenesis, neurogenesis and neuroinflammation (Ransom et al., 2003) . Since 5-HT 7 receptors are positively linked to cAMP accumulation, cellular events associated with the cAMP/protein kinase A pathway in glial cells may be considered as candidate functions of these receptors. Interestingly enough, among these are the release of neurotrophic factors and of inflammatory cytokines (Huneycutt & Benveniste, 1995) .
In conclusion, human glioblastoma cell lines express functional 5-HT 7 receptors and the three splice variants of the corresponding mRNA. These cell lines could serve as model systems of native 5-HT 7 receptors in glial cells to investigate their putative role in processes like release of neurotrophic factors or inflammatory cytokines.
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